A global team of scientists, innovators, and future-thinkers: Synchron, Inc.

The Silicon Review

Synchron, Inc. stands at the forefront of medical innovation, pioneering the development of minimally invasive neuromodulation technologies since its inception in 2012. With a steadfast commitment to revolutionizing neurological treatment, Synchron has emerged as a trailblazing force in the healthcare industry, spearheading groundbreaking advancements that promise to redefine the landscape of neurology. Headquartered in the vibrant heart of Silicon Valley, Synchron embodies the spirit of innovation and ingenuity that defines the region. Drawing upon a diverse team of experts hailing from various disciplines, the company is driven by a collective vision to harness cutting-edge technology in service of improving patient outcomes and enhancing quality of life. Central to Synchron's mission is the development of the world's first endovascular neural interface, the StentrodeTM. This groundbreaking technology represents a paradigm shift in neurostimulation, offering a minimally invasive alternative to traditional surgical procedures. By leveraging the body's natural vasculature, the StentrodeTM bypasses the need for open brain surgery, thus reducing risk and improving patient comfort.

A pivotal milestone in Synchron's journey is its acquisition of SmartStent Pty Ltd, an Australian company renowned for its pioneering work in implantable neurotechnologies. With exclusive intellectual property rights to the innovative StentrodeTM technology, SmartStent brings a wealth of expertise and resources to Synchron's expanding portfolio. This strategic partnership not only strengthens Synchron's position as a global leader in neuromodulation but also accelerates the advancement of the StentrodeTM towards commercialization. At the core of Synchron's ethos is a relentless pursuit of excellence in research and development. The company's pioneering work in neuromodulation has garnered recognition and support from prestigious institutions, including the U.S. Defense Advanced Research Projects Agency (DARPA). Through strategic collaborations and partnerships with leading academic institutions and industry stakeholders, Synchron remains at the forefront of scientific innovation, driving forward the frontiers of neurotechnology.

Beyond its technological achievements, Synchron is guided by a deep commitment to patient-centric care and ethical practice. With a steadfast focus on safety, efficacy, and accessibility, the company strives to ensure that its innovations are not only transformative but also sustainable and inclusive. By prioritizing the needs and well-being of patients, Synchron aims to empower individuals to reclaim control over their health and unlock new possibilities for treatment and recovery. As Synchron continues to chart new territories in the field of neuromodulation, it remains steadfast in its dedication to pushing the boundaries of what is possible. With a dynamic team of visionaries and innovators leading the charge, the company is poised to revolutionize the way neurological conditions are diagnosed and treated. Through relentless innovation, unwavering commitment, and a passion for improving lives, Synchron is shaping the future of healthcare, one breakthrough at a time.

Functional Neurointervention

Synchron's Endovascular platform heralds a new era in medical innovation, introducing the paradigm of Functional Neurointervention to revolutionize the treatment of neurological disorders. This pioneering approach represents a seismic shift in neurosurgical techniques, offering a minimally invasive alternative to traditional open brain surgery. At the heart of Synchron's Endovascular platform lies the innovative Stentrode, a cutting-edge electrode array designed to navigate the intricate network of blood vessels and access the brain's neural pathways. Unlike conventional brain computer interface (BCI) technologies that require invasive surgical procedures, the Stentrode enables seamless delivery of electronics throughout the brain without the need for incisions or craniotomies.

The Stentrode serves as the cornerstone of Synchron's neurointerventional electrophysiology (NeuroEP) platform, facilitating a myriad of applications including brain mapping, brain monitoring, and deep brain stimulation. By leveraging the body's natural vasculature as conduits for intervention, Synchron's Endovascular approach unlocks unprecedented access to the brain, paving the way for transformative advancements in neurological care. Central to the Endovascular platform's transformative potential is its unparalleled reach and scalability. With thousands of blood vessels serving as uncharted highways into the brain, Synchron's approach offers a vast network of access points, facilitating widespread adoption and dissemination of neurointerventional procedures. This expansive reach is further amplified by a global network of tens of thousands of interventional physicians, providing a robust clinical infrastructure ten times larger than that of traditional BCI technologies. Moreover, Synchron's Endovascular platform presents a unique opportunity to harness vast quantities of functional brain data on an unprecedented scale. By pioneering a first-to-market approach, Synchron is poised to set a new gold standard in endovascular functional brain data, unlocking invaluable insights into the inner workings of the brain and paving the way for groundbreaking discoveries in neuroscience.

Looking ahead, Synchron envisions a future where Functional Neurointervention becomes the cornerstone of neurological treatment, offering personalized and precise interventions tailored to each patient's unique needs. Over the next decade, the company is committed to realizing this vision by further advancing the capabilities of the Stentrode and expanding the scope of neurointerventional techniques to encompass a comprehensive suite of therapeutic modalities. Through relentless innovation, unwavering dedication, and a steadfast commitment to patient-centric care, Synchron is poised to redefine the landscape of neurology and usher in a new era of hope and healing for millions of patients worldwide. With its Endovascular platform at the forefront of this revolution, Synchron is shaping the future of medicine one breakthrough at a time.

Tom Oxley, CEO